A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation
Open Access
- 18 June 2010
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 37 (1), 164-172
- https://doi.org/10.1183/09031936.00068310
Abstract
Azithromycin reduces airway inflammation and improves forced expiratory volume in 1 s (FEV1) in chronic rejection or bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). Azithromycin prophylaxis might prevent BOS. A double-blind randomised controlled trial of azithromycin (n = 40) or placebo (n = 43), initiated at discharge and administered three times a week for 2 yrs, was performed in 2005–2009 at the Leuven University Hospital (Leuven, Belgium). Primary end-points were BOS-free and overall survival 2 yrs after LTx; secondary end-points were acute rejection, lymphocytic bronchiolitis and pneumonitis rate, prevalence of pseudomonal airway colonisation or gastro-oesophageal reflux, and change in FEV1, airway and systemic inflammation over time. Patients developing BOS were assessed for change in FEV1 with open-label azithromycin. BOS occurred less in patients receiving azithromycin: 12.5 versus 44.2% (p = 0.0017). BOS-free survival was better with azithromycin (hazard ratio 0.27, 95% CI 0.092–0.816; p = 0.020). Overall survival, acute rejection, lymphocytic bronchiolitis, pneumonitis, colonisation and reflux were comparable between groups. Patients receiving azithromycin demonstrated better FEV1 (p = 0.028), and lower airway neutrophilia (p = 0.015) and systemic C-reactive protein levels (p = 0.050) over time. Open-label azithromycin for BOS improved FEV1 in 52.2% patients. No serious adverse events were noted. Azithromycin prophylaxis attenuates local and systemic inflammation, improves FEV1 and reduces BOS 2 yrs after LTx.Keywords
This publication has 27 references indexed in Scilit:
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report—2009The Journal of Heart and Lung Transplantation, 2009
- Obliterative bronchiolitis following lung transplantation: from old to new concepts?Transplant International, 2009
- Chronic Lung Allograft Rejection: Mechanisms and TherapyProceedings of the American Thoracic Society, 2009
- Bronchiolitis Obliterans Syndrome: Alloimmune-Dependent and -Independent Injury with Aberrant Tissue RemodelingSeminars in Thoracic and Cardiovascular Surgery, 2008
- Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung RejectionThe Journal of Heart and Lung Transplantation, 2007
- Transplantation — A Medical Miracle of the 20th CenturyThe New England Journal of Medicine, 2004
- Bronchiolitis Obliterans after Human Lung TransplantationAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteriaThe Journal of Heart and Lung Transplantation, 2002
- Center-Specific Graft and Patient Survival RatesJAMA, 1998
- Post-Transplant Obliterative Bronchiolitis and Other Late Lung Sequelae in Human Heart-Lung TransplantationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1984